#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Depression Scleroderma associated digital ulcer Glioblastoma multiforme Palmoplantar pustulosis Leiomyosarcoma recurrent Cardiomyopathy Hereditary haemorrhagic telangiectasia Gastrointestinal disorder Ichthyosis Duchenne muscular dystrophy Duchenne muscular dystrophy gene carrier Propionic acidaemia Von Willebrand's disease Mantle cell lymphoma recurrent Paget's disease of the vulva More trials…

    Learn about Rare Diseases

    Paroxysmal nocturnal haemoglobinuria Thrombotic thrombocytopenic purpura Hairy cell leukaemia Hereditary motor and sensory neuropathy – Life with Disease Marginal zone lymphoma refractory – Treatment Antisynthetase syndrome – Treatment Tuberous sclerosis complex – Life with Disease Ocular melanoma – Trials in Disease Pleomorphic leiomyosarcoma Nephroblastoma – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Eplontersen Ropeginterferon Alfa-2B Cctx-001 Filgotinib Lisinopril Dihydrate [18F]Alf-Nota-Octreotide Diltiazem Hydrochloride Ro7589655 TORASEMIDE Quetiapine GXV813 Ursodoxicoltaurine GSKVX000000030810 IM-101 T89 Dexpanthenol Emraclidine VOTOPLAM Axitinib Orismilast More therapies…

    Learn about Your Condition

    Spondylolisthesis Bronchitis Brain stem glioma Gastrointestinal carcinoma Lung neoplasm malignant Endometrial cancer stage IV Vulval cancer recurrent Herpes zoster Post procedural complication Lymphoma Vulvovaginal candidiasis Cerebral haemorrhage Reperfusion injury Pneumonia chlamydial Malignant melanoma of eyelid More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Cholangiocarcinoma

  • Study of cisplatin, gemcitabine and rilvegostomig treatment in patients with high-risk resectable intrahepatic cholangiocarcinoma

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Rilvegostomig
    • Cisplatin
    • Gemcitabine
    France

  • Study of CYC140 oral medication for patients with advanced solid tumors and lymphoma

    Not recruiting

    1 1 1
    Investigated Diseases:
    • Gallbladder cancer
    • B-cell lymphoma
    • Bladder cancer
    Investigated Drugs:
    • Cyc140 Monohydrochloride Monohydrate
    Spain

  • Study of Pemigatinib for Patients with Advanced Intrahepatic Cholangiocarcinoma with FGFR2 Changes After Local Therapy

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Pemigatinib
    Germany

  • Study Comparing Pemigatinib and Gemcitabine Plus Cisplatin for First-Line Treatment in Patients with Unresectable or Metastatic Cholangiocarcinoma with FGFR2 Rearrangement

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Cholangiocarcinoma
    Investigated Drugs:
    • Pemigatinib
    • Cisplatin
    • Gemcitabine
    Austria Belgium France Germany Italy The Netherlands +2

  • Study of Durvalumab, Tremelimumab, and Capecitabine for Patients with Biliary Tract Cancer in an Adjuvant Setting

    Not recruiting

    2 1 1 1
    Investigated Diseases:
    • Biliary adenoma
    • Biliary tract operation
    • Gallbladder cancer
    Investigated Drugs:
    • Tremelimumab
    • Capecitabine
    • Durvalumab
    Germany

  • Study on Gemcitabine and Cisplatin for Patients After Surgery for Bile Duct or Gallbladder Cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Gallbladder cancer
    • Cholangiocarcinoma
    Investigated Drugs:
    • Capecitabine
    • Cisplatin
    • Gemcitabine Hydrochloride
    Austria Germany Italy The Netherlands
Previous Page
1 … 3 4 5 6 7
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!